These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36335273)

  • 21. Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center.
    Chapman-Davis E; Zhou ZN; Fields JC; Frey MK; Jordan B; Sapra KJ; Chatterjee-Paer S; Carlson AD; Holcomb KM
    J Gen Intern Med; 2021 Jan; 36(1):35-42. PubMed ID: 32720237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine.
    Samusieva A; Serga S; Klymenko S; Rybchenko L; Klimuk B; Zakhartseva L; Gorovenko N; Lobanova O; Rossokha Z; Fishchuk L; Levkovich N; Medvedieva N; Popova O; Cheshuk V; Inomistova M; Khranovska N; Skachkova O; Michailovich Y; Ponomarova O; Kozeretska I
    Breast Cancer Res Treat; 2022 Oct; 195(3):453-459. PubMed ID: 35930098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Participation of Korean families at high risk for hereditary breast and ovarian cancer in BRCA1/2 genetic testing.
    Sun Y; Kang E; Baek H; Jung J; Hwang E; Koo J; Kim EK; Kim SW
    Jpn J Clin Oncol; 2015 Jun; 45(6):527-32. PubMed ID: 25838294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.
    Daly MB; Pilarski R; Axilbund JE; Berry M; Buys SS; Crawford B; Farmer M; Friedman S; Garber JE; Khan S; Klein C; Kohlmann W; Kurian A; Litton JK; Madlensky L; Marcom PK; Merajver SD; Offit K; Pal T; Rana H; Reiser G; Robson ME; Shannon KM; Swisher E; Voian NC; Weitzel JN; Whelan A; Wick MJ; Wiesner GL; Dwyer M; Kumar R; Darlow S
    J Natl Compr Canc Netw; 2016 Feb; 14(2):153-62. PubMed ID: 26850485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population prevalence of individuals meeting criteria for hereditary breast and ovarian cancer testing.
    Greenberg S; Buys SS; Edwards SL; Espinel W; Fraser A; Gammon A; Hafen B; Herget KA; Kohlmann W; Roundy C; Sweeney C
    Cancer Med; 2019 Nov; 8(15):6789-6798. PubMed ID: 31531966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines.
    Chun DS; Berse B; Venne VL; DuVall SL; Filipski KK; Kelley MJ; Meyer LJ; Icardi MS; Lynch JA
    Fam Cancer; 2017 Jan; 16(1):41-49. PubMed ID: 27589855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of
    Pilarski R
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():79-86. PubMed ID: 31099688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer genetics knowledge and beliefs and receipt of results in Ashkenazi Jewish individuals receiving counseling for BRCA1/2 mutations.
    Kelly K; Leventhal H; Marvin M; Toppmeyer D; Baran J; Schwalb M
    Cancer Control; 2004; 11(4):236-44. PubMed ID: 15284715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
    Daly MB; Pilarski R; Yurgelun MB; Berry MP; Buys SS; Dickson P; Domchek SM; Elkhanany A; Friedman S; Garber JE; Goggins M; Hutton ML; Khan S; Klein C; Kohlmann W; Kurian AW; Laronga C; Litton JK; Mak JS; Menendez CS; Merajver SD; Norquist BS; Offit K; Pal T; Pederson HJ; Reiser G; Shannon KM; Visvanathan K; Weitzel JN; Wick MJ; Wisinski KB; Dwyer MA; Darlow SD
    J Natl Compr Canc Netw; 2020 Apr; 18(4):380-391. PubMed ID: 32259785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms to increase cascade testing in hereditary breast and ovarian cancer: Impact of introducing standardized communication aids into genetic counseling.
    Garcia C; Sullivan MW; Lothamer H; Harrison KM; Chatfield L; Thomas MH; Modesitt SC
    J Obstet Gynaecol Res; 2020 Sep; 46(9):1835-1841. PubMed ID: 32656916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of the cost-effectiveness of genetic testing for germline variants in familial cancer.
    Teppala S; Hodgkinson B; Hayes S; Scuffham P; Tuffaha H
    J Med Econ; 2023; 26(1):19-33. PubMed ID: 36426964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation.
    Hull LE; Haas JS; Simon SR
    Am J Prev Med; 2018 Feb; 54(2):221-228. PubMed ID: 29241717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA1 genetic testing in a Pakistani breast-ovarian cancer family with multiple consanguineous marriages.
    Rashid MU; Muhammad N; Iqbal K; Yusuf HA; Hamann U
    Clin Genet; 2015 Aug; 88(2):198-9. PubMed ID: 25430881
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling.
    Liede A; Metcalfe K; Hanna D; Hoodfar E; Snyder C; Durham C; Lynch HT; Narod SA
    Am J Hum Genet; 2000 Dec; 67(6):1494-504. PubMed ID: 11063672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
    PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    Daly MB; Pal T; Berry MP; Buys SS; Dickson P; Domchek SM; Elkhanany A; Friedman S; Goggins M; Hutton ML; ; Karlan BY; Khan S; Klein C; Kohlmann W; ; Kurian AW; Laronga C; Litton JK; Mak JS; ; Menendez CS; Merajver SD; Norquist BS; Offit K; Pederson HJ; Reiser G; ; Senter-Jamieson L; ; Shannon KM; Shatsky R; Visvanathan K; Weitzel JN; Wick MJ; Wisinski KB; Yurgelun MB; Darlow SD; Dwyer MA
    J Natl Compr Canc Netw; 2021 Jan; 19(1):77-102. PubMed ID: 33406487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care: A Cluster Randomized Clinical Trial.
    Kukafka R; Pan S; Silverman T; Zhang T; Chung WK; Terry MB; Fleck E; Younge RG; Trivedi MS; McGuinness JE; He T; Dimond J; Crew KD
    JAMA Netw Open; 2022 Jul; 5(7):e2222092. PubMed ID: 35849397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic medicine is accelerating in Japan.
    Hayashi S; Kubo M; Kaneshiro K; Kai M; Yamada M; Morisaki T; Takao Y; Shimazaki A; Shikada S; Nakamura M
    Breast Cancer; 2022 Jul; 29(4):659-665. PubMed ID: 35191009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opportunities for improving triple-negative breast cancer outcomes: results of a population-based study.
    Rapiti E; Pinaud K; Chappuis PO; Viassolo V; Ayme A; Neyroud-Caspar I; Usel M; Bouchardy C
    Cancer Med; 2017 Mar; 6(3):526-536. PubMed ID: 28211614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.